Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EP Biocomposites's Days Sales Outstanding for the
six
months ended in Mar. 2026 was 206.01.
EP Biocomposites's Days Inventory for the
six
months ended in Mar. 2026 was 47.42.
EP Biocomposites's Days Payable for the
six
months ended in Mar. 2026 was 55.14.
Therefore, EP Biocomposites's Cash Conversion Cycle (CCC) for the
six
months ended in Mar. 2026 was 198.29.
EP Biocomposites (BOM:543595) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
EP Biocomposites Cash Conversion Cycle Related Terms
EP Biocomposites Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for EP Biocomposites's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:543595 vs TT, JCI, CARR: Cash Conversion Cycle Comparison
For the Building Products & Equipment subindustry, EP Biocomposites's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EP Biocomposites Cash Conversion Cycle vs Construction Industry
For the Construction industry and Industrials sector, EP Biocomposites's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where EP Biocomposites's Cash Conversion Cycle falls into.
EP Biocomposites Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
EP Biocomposites's Cash Conversion Cycle for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EP Biocomposites (BOM:543595) has a Cash Conversion Cycle of 198.29 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on EP Biocomposites and its competitors.
Is EP Biocomposites' Cash Conversion Cycle too high?
EP Biocomposites' current Cash Conversion Cycle is 198.29. The Construction industry median Cash Conversion Cycle is 55.88. EP Biocomposites' value of 198.29 is 254.8% above this industry median. Overall, EP Biocomposites has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does EP Biocomposites' Cash Conversion Cycle compare to TT and JCI?
EP Biocomposites' Cash Conversion Cycle of 198.29 can be compared against companies in the Construction industry. The industry median Cash Conversion Cycle is 55.88. EP Biocomposites' value of 198.29 is 254.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Construction company?
The median Cash Conversion Cycle among Construction companies is 55.88, based on 1,766 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. EP Biocomposites's current Cash Conversion Cycle of 198.29 is 254.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on EP Biocomposites and its competitors. For the Construction industry, the median Cash Conversion Cycle is 55.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EP Biocomposites's current Cash Conversion Cycle is 198.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EP Biocomposites stock overvalued right now?
Based on GuruFocus' analysis, EP Biocomposites (BOM:543595) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹201.91, compared to a current price of ₹106.00 — trading 47.5% below its estimated fair value. The current Cash Conversion Cycle is 198.29 and 254.8% above the Construction industry median of 55.88. EP Biocomposites' overall GF Score™ is 76/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For EP Biocomposites (BOM:543595), the current Cash Conversion Cycle is 198.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is EP Biocomposites (BOM:543595) Overvalued in 2026?
Based on GuruFocus' analysis, EP Biocomposites stock appears to be undervalued.
The current stock price of ₹106.00 is trading 47.5% below its estimated GF Value™ of ₹201.91.
GuruFocus considers EP Biocomposites to be Significantly Undervalued.
Key valuation signals for BOM:543595:
Cash Conversion Cycle: 198.29
GF Value™: ₹201.91 vs. price of ₹106.00 (47.5% below fair value)
Industry Position: 254.8% above the Construction median
No single metric tells the full story. See the BOM:543595 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
EP Biocomposites Ltd is the manufacturer and supplier of fibre reinforced polymers products such as door shutters, frames, Biodigestor Tanks, Bio toilets and allied products for construction and Industrial applications. The company focus on giving sanitation solutions to those who do not have access to toilets, as well as to those who have toilets but face trouble treating and managing the waste through septic tanks. The company also provides sanitation infrastructure and human waste management solutions and services, involving simple bio-digester technology licensed from the Defence Research and Development Organisation (DRDO) and Industry Interface and Technology Management, operating under the aegis of DRDO, Ministry of Defence, Government of India.
76GF Score
Get the complete analysis for BOM:543595
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543595 has been successfully added to your 
